Ocular Therapeutix, Inc. (OCUL): Earnings News

OCUL – Seeing EPS loss estimates beat range from $0.01-$0.08. Slightly misses on revenues.

Key Facts Surrounding This News Item

  • OCUL had a POWR Rating of D (Sell) coming into today.
  • OCUL was 8.74% above its 10-Day Moving Average coming into today.
  • OCUL was 13.69% above its 20-Day Moving Average coming into today.
  • OCUL was 13.89% above its 50-Day Moving Average coming into today.
  • OCUL was 16.47% above its 100-Day Moving Average coming into today.
  • OCUL was -6.45% below its 200-Day Moving Average coming into today.
  • OCUL had returned +33.71% year-to-date leading up to today’s news, versus a +2.22% return from the benchmark S&P 500 during the same period.

More Info About Ocular Therapeutix, Inc. (OCUL)

Ocular Therapeutix is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. The company was founded in 2006 and is based in Bedford, Massachusetts. View our full OCUL ticker page with ratings, news, and more.

OCUL at a Glance

OCUL Current POWR Rating™
Overall POWR Rating™
OCUL Current Price $5.73 1.72%
More OCUL Ratings, Data, and News

OCUL Price Reaction

The day of this event (Mar. 8, 2018)
OCUL Closing Price$5.86 1.51%
OCUL Volume810,700
11.94% from avg
Leading up to this event
OCUL 1-mo return18.29%
After this event
OCUL 1-day return0.85%
OCUL 3-day return6.00%
OCUL 5-day return7.61%

OCUL Price Chart

The Top Stocks For 2019

More Ocular Therapeutix, Inc. (OCUL) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All OCUL News
Page generated in 0.9008 seconds.